ArticleBMC infectious diseases2026
Characterization of secondary bacterial infections in Buruli ulcer disease in Ghana: a focus on antimicrobial resistant Staphylococcus aureus.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundBuruli ulcer (BU), caused by Mycobacterium ulcerans, is a chronic necrotizing skin disease often complicated by secondary bacterial infections that may delay healing and worsen clinical outcomes. Among these, Staphylococcus aureus is frequently implicated; however, the broader spectrum of bacterial colonizers and their antimicrobial resistance patterns in BU lesions remain inadequately characterized. This study aimed to characterize secondary bacterial infections in BU lesions, with a particular focus on the frequency, antimicrobial resistance profile, and methicillin resistance determinants of S. aureus.
methodsFrom October 2023 to March 2025, wound swabs were collected from PCR-confirmed BU patients across three endemic districts in Ghana before the start of BU-specific antibiotic treatment. Bacterial isolates were cultured and identified using standard microbiological techniques and the BioMérieux VITEK 2 compact system. Antimicrobial susceptibility testing was interpreted according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines. Molecular detection of the mecA gene was performed using conventional polymerase chain reaction (PCR) with agarose gel electrophoresis confirmation.
resultsA total of 83 bacterial isolates representing 18 genera were recovered from 31 of 40 BU patients. Gram-positive bacteria accounted for 56.6% (47/83) of isolates, while Gram-negative organisms constituted 43.4% (36/83). Staphylococcus aureus was the predominant species (17/83; 20.4%). The isolates exhibited high resistance to benzylpenicillin (94%) and tetracycline (82%), but retained complete susceptibility (100%) to linezolid, moxifloxacin, and quinupristin/dalfopristin. The mecA gene was detected in 94.1% of S. aureus isolates, indicating a high prevalence of methicillin-resistant S. aureus (MRSA). Notably, PCR-based detection identified a higher proportion of MRSA compared with phenotypic methods (94.1% vs. 58.8%).
conclusionSecondary bacterial infections in BU lesions are microbiologically diverse, with S. aureus emerging as a predominant and clinically significant pathogen. The high prevalence of MRSA highlights the need for integrated management strategies addressing both M. ulcerans and co-infecting bacteria. Furthermore, reliance on phenotypic methods alone may underestimate MRSA burden, underscoring the importance of incorporating molecular diagnostics into routine surveillance and clinical care in endemic settings. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.